CareDx, Inc logo CDNA - CareDx, Inc

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY 0
BUY 11
HOLD 3
SELL 0
STRONG
SELL 0
| PRICE TARGET: $62.25 DETAILS
HIGH: $74.00
LOW: $46.00
MEDIAN: $64.50
CONSENSUS: $62.25
DOWNSIDE: 10.06%

Stock News

CareDx Announces New KOAR Data Linking Elevated AlloSure® Kidney to Nearly 3-Fold Higher Risk of Adverse Graft Outcomes in Patients with Borderline Rejection or TCMR at ASN Kidney Week 2026

CareDx Announces New KOAR Data Linking Elevated AlloSure® Kidney to Nearly 3-Fold Higher Risk of Adverse Graft Outcomes in Patients with Borderline Rejection or TCMR at ASN Kidney Week 2026

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today highlighted data featuring AlloSure® Kidney donor-derived cell-free DNA (dd-cfDNA) being presented at the American Society of Nephrology (ASN) Kidney Week 2026, taking place October 22–25 in Denver, Colorado. The findings address several persistent challenges in kidney transplant management: determining the significance of a.

Oct 22, 2026 03:05 AM • businesswire.com
CareDx to Report Third Quarter 2026 Financial Results on October 29, 2026

CareDx to Report Third Quarter 2026 Financial Results on October 29, 2026

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced it will report financial results for the third quarter 2026 after market close on Thursday, October 29, 2026. The Company will host a webcast and conference call that day at 1:30 p.m. PT / 4:30 p.m. ET. A live and archived webcast of the conference call can be accessed on the Events & Presentations section of C.

Oct 15, 2026 12:01 PM • businesswire.com
Critical Contrast: CollPlant Biotechnologies (NASDAQ:CLGN) & CareDx (NASDAQ:CDNA)

Critical Contrast: CollPlant Biotechnologies (NASDAQ:CLGN) & CareDx (NASDAQ:CDNA)

CareDx (NASDAQ: CDNA - Get Free Report) and CollPlant Biotechnologies (NASDAQ: CLGN - Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, institutional ownership, valuation, risk and earnings. Risk and Volatility CareDx has a beta of 2.38,

Oct 05, 2026 06:14 AM • defenseworld.net
CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced the award of inducement grants. On August 5, 2026, as an inducement material to acceptance of employment with CareDx, 35 new employees were awarded restricted stock units (RSUs) for an aggregate of 97,090 shares of common stock. With respect to 34 of the new employees, an aggregate of 93,090 of the RSUs will vest o.

Aug 07, 2026 12:01 PM • businesswire.com
CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced that, on July 30, 2026, CareDx granted to James McNally, the Company's newly appointed Executive Advisor, certain stock awards as an inducement material to Mr. McNally's employment with CareDx. CareDx granted 15,822 shares of common stock restricted stock units (RSUs) to Mr. McNally. The RSU awards were made pursua.

Jul 31, 2026 02:45 PM • businesswire.com

Price Targets